Delphinus SoftVue Prospective Case Collection - ARM 1

MEDICAL DEVICES: * SoftVue™ (SV) automated whole breast ultrasound system, 510(k) Cleared for B-Mode ultrasound breast imaging, manufactured by Delphinus Medical Technologies. * SoftVue™ with device modifications (software, hardware, user-interface), safety-tested for human use to complete feasibility, verification, and validation testing as a routine part of product development and performed in accordance with FDA 21 CFR 812.2 (b), manufactured by Delphinus Medical Technologies. * Full-field digital mammography (FFDM), FDA Approved for breast screening and diagnosis, various manufacturers. * Digital breast tomosynthesis (DBT), FDA Approved for breast screening and diagnosis, various manufacturers. OBJECTIVES: * Primary: To establish a library of cases for use in future SoftVue™ research studies, user training, and marketing. * Secondary: Determine the frequency and severity of adverse events (AEs) to further evaluate the safety of SoftVue. ENDPOINTS: From multiple clinical sites whichever comes first: * Up to 17,500 total enrolled subjects * Up to 105 total breast cancer cases detected at program entry screening * At least 35 total discordant breast cancer cases, where FFDM is negative or benign (BI-RADS 1 or 2) but SV is incomplete (BIRADS 0) and diagnostic imaging workup of SV findings leads to breast biopsy with malignant pathology SITES: At least six (≥ 6) qualified clinical sites in the United States * MQSA Certified * Digital Breast Tomosynthesis Screening Program Implemented * Academic, Community Hospital, or Private Practice Setting PROJECT DESIGN AND PROCEDURES: * Potential participants will be recruited from the group of women presenting for their annual breast imaging exams at multiple clinical sites utilizing 3D DBT and 2D FFDM (non-synthesized) for routine screening. * Asymptomatic women with heterogeneously or extremely dense breast parenchyma (BI-RADS composition c or d), based on visual assessment of FFDM by trained site personnel, will be invited to consider volunteering to participate in the case collection program. * All participants will complete the same routine screening FFDM + DBT evaluation for which they originally reported to the clinic, with a complete set of 2D views and 3D views. * Eligible patients will receive SV as an adjunct to FFDM + DBT. * A single Investigator (radiologist) at each site will perform sequential review of the same subjects FFDM, DBT, and SV images. * FFDM will be evaluated for final parenchymal density (BI-RADS a through d) and then each exam will be assigned to one of 3 BI-RADS assessment categories (0, 1, 2) by the radiologist. * Abnormal findings will be indicated by a BI-RADS assessment category of 0 (Incomplete)and will undergo diagnostic imaging evaluations consistent with universally accepted standards of care. * All evaluation results, diagnosis and treatment outcomes will be recorded. * Normal findings will be indicated by BI-RADS assessment categories of 1 or 2 (Negative or Benign) which will be associated with a management recommendation to resume routine screening in one year, unless symptoms or signs of breast cancer develop in the interim. * All participants who are not diagnosed with breast cancer as a direct result of the program entry examinations, incidental evaluations, or interval symptoms, will return to the site in 12 months for their next annual screening exam, the results and outcome of which will be recorded. * Cancer status for all participants will be surveyed from program entry until and including the completion of recommended follow-up. * A case will be determined cancer negative if the participant has no findings suspicious for cancer throughout the interval between program entry and completion of annual follow-up. * A case will be determined cancer positive if a pathological evaluation confirms a breast cancer diagnosis during the interval between program entry and completion of annual follow-up. STATISTICAL ANALYSIS: * Demographic characteristics (age, race, and ethnicity) and other baseline characteristics (e.g., project arm, project site, breast density, lesion-specific characteristics) will be tabulated for all participants. * A flow diagram or table will illustrate patient disposition ("accountability of patient cohort") including reasons for ineligibility and/or unevaluability. * Safety will be summarized for all enrolled women. With the exception of anticipated events, adverse events (AEs) and serious adverse events (SAEs), occurring from the time of enrollment (SoftVue) and for 24 hours following the conclusion of the SoftVue exam, will be recorded. * A separate statistical plan will be developed for any future analysis that includes justification of sample size and, if applicable to the requirements of FDAAA 801, will be registered separately in order to share the results.